Comparative Pharmacology
Head-to-head clinical analysis: IBUPROHM COLD AND SINUS versus VOLTAREN XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IBUPROHM COLD AND SINUS versus VOLTAREN XR.
IBUPROHM COLD AND SINUS vs VOLTAREN-XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, leading to anti-inflammatory, analgesic, and antipyretic effects. Pseudoephedrine is a sympathomimetic amine that acts as a vasoconstrictor via alpha-adrenergic receptors in nasal mucosa, reducing nasal congestion.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. This leads to anti-inflammatory, analgesic, and antipyretic effects.
1-2 tablets (each containing ibuprofen 200 mg and pseudoephedrine 30 mg) orally every 4-6 hours as needed; maximum daily dose: 6 tablets (ibuprofen 1200 mg, pseudoephedrine 180 mg).
100 mg orally once daily, extended-release formulation. Maximum 150 mg/day (divided as 75 mg twice daily or 100 mg once daily).
None Documented
None Documented
1.8–2.5 hours in adults; prolonged to 3–4 hours in elderly or hepatic impairment due to reduced clearance.
The terminal elimination half-life is approximately 2 hours. The extended-release formulation (XR) does not alter the half-life; it maintains prolonged therapeutic plasma concentrations with twice-daily dosing.
Renal excretion of unchanged drug and metabolites accounts for >90% of elimination, with approximately 1% excreted as unchanged ibuprofen. Biliary/fecal excretion is <10%.
Approximately 65% of a dose is excreted renally as unchanged drug and metabolites (primarily as glucuronide conjugates); about 35% is eliminated via bile in feces.
Category C
Category C
NSAID/Decongestant Combination
NSAID